


Journal Pre-proof

E-cigarettes, Vaping-Related Pulmonary Illnesses, and asthma: A Perspective from Inhalation Toxicologists

Phillip W. Clapp, Ph.D, David B. Peden, MD, Ilona Jaspers, Ph.D



PII: S0091-6749(19)31482-4

DOI: <https://doi.org/10.1016/j.jaci.2019.11.001>

Reference: YMAI 14251

To appear in: *Journal of Allergy and Clinical Immunology*

Received Date: 27 September 2019

Revised Date: 21 October 2019

Accepted Date: 5 November 2019

Please cite this article as: Clapp PW, Peden DB, Jaspers I, E-cigarettes, Vaping-Related Pulmonary Illnesses, and asthma: A Perspective from Inhalation Toxicologists, *Journal of Allergy and Clinical Immunology* (2019), doi: <https://doi.org/10.1016/j.jaci.2019.11.001>.

This is a PDF file of an article that has undergone enhancements after acceptance, such as the addition of a cover page and metadata, and formatting for readability, but it is not yet the definitive version of record. This version will undergo additional copyediting, typesetting and review before it is published in its final form, but we are providing this version to give early visibility of the article. Please note that, during the production process, errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

© 2019 Published by Elsevier Inc. on behalf of the American Academy of Allergy, Asthma & Immunology.

**E-cigarettes, Vaping-Related Pulmonary Illnesses, and asthma: A Perspective from
Inhalation Toxicologists**

Phillip W. Clapp, Ph.D¹, David B. Peden, MD^{1,2,3}, Ilona Jaspers, Ph.D^{1,2,3}

¹Center for Environmental Medicine, Asthma and Lung Biology

²Department of Pediatrics

³Curriculum on Toxicology and Environmental Medicine

University of North Carolina at Chapel Hill

Corresponding Author:

Ilona Jaspers, Ph.D.

Professor, Departments of Pediatrics, Microbiology & Immunology, and Environmental Sciences
and Engineering

Director, Curriculum in Toxicology & Environmental Medicine

Deputy Director, Center for Environmental Medicine, Asthma, and Lung Biology

University of North Carolina at Chapel Hill

116 Manning Drive

Chapel Hill, NC 27599-7310

Phone: 919. 966. 9863

Ilona_jaspers@med.unc.edu

Keywords: E-cigarettes, vaping, toxicology, asthma

None of the authors have a conflict of interest to disclose.

Introduction

The recent outbreak of e-cigarette, or vaping-product use associated lung injury (EVALI) is alarming. As of October 18th, 2019, thirty-three deaths and nearly 1500 hospitalizations associated with e-cigarette use have been reported in 49 states and the US Virgin Islands. Initial epidemiological investigations of EVALI cases in Illinois and Wisconsin identified that over 80% of the reported cases occurred in young, white, males who presented with respiratory, gastrointestinal, and constitutional symptoms, which rapidly progressed to severe acute lung injury (1). Interestingly, underlying asthma was reported in 30% of these cases, which is much higher than the 8-10% of asthmatics seen in the general population. While many questions regarding the safety of e-cigarettes have come to the forefront with the emergence of EVALI, health care providers and concerned parents are also asking what may be causing this outbreak and who may be susceptible to developing EVALI.

Historical Context

E-cigarettes were first marketed in the US as harm-reduction products and tools to help smoking cessation. However, neither the safety nor the efficacy of these products as cessation aids had been evaluated. In 2015, Public Health England (PHE), an executive agency of the Department of Health and Social Care in the United Kingdom, declared e-cigarettes to be 95% safer than traditional cigarettes stating that, "While vaping may not be 100% safe, most of the chemicals causing smoking-related disease are absent and the chemicals that are present pose limited danger." While PHE's statement was largely based on the presence and level of known cancer-causing chemicals in cigarette smoke, the toxicity of inhaling flavoring agents and chemicals unique to e-cigarettes was unclear. Indeed, some e-cigarette flavoring agents have been associated with greater toxicity in experimental models and thermal decomposition of flavoring agents during vaporization at high power settings can produce chemicals with known toxicities (2). Furthermore, limited regulation of the e-cigarette industry has allowed new devices and e-liquids to enter the e-cigarette market at such a rapid pace that adequate toxicity and safety testing emerging products is not possible. Hence, early statements about their safety were made without sufficient supporting data.

Data from randomized controlled trials (RCTs) evaluating the effectiveness of e-cigarettes as cessation aids are currently being collected. A study recently published in the New England

Journal of Medicine identified that e-cigarette use, in conjunction with behavioral support, improved smoking cessation in adults attempting to quit when compared to nicotine-replacement-therapy with behavioral support (18% versus 9.9%, respectively) (3). However, 80% of e-cigarette users in this study continued vaping after 1 year whereas only 9% of nicotine-replacement product users continued product use after 1 year. This is concerning as additional work indicates that vaping more than one year after quitting smoking is associated with smoking relapse (4). Ultimately, evidence supporting the effectiveness of e-cigarettes as cessation tools must be balanced against the short-term and long-term safety of these products.

Despite the ongoing debate regarding the efficacy of e-cigarettes as effective smoking cessation tools, asthmatics who currently smoke are often advised by their health care providers to switch to e-cigarettes as a safer alternative (5). More alarming are surveys demonstrating that e-cig use is more popular among asthmatic teenagers as compared to their non-asthmatic peers (6). A recent study of 6089 U.S. high school students found that e-cig use was independently associated with asthma (6). Similarly, a cross-sectional study of 35,904 South Korean high school students found that e-cig use had an increased association with asthma and asthmatic vapers missed school more frequently due to severe asthma symptoms (as reviewed in (2)). Data from the Florida Youth Tobacco Survey indicate that 33% of 11- to 17-year-olds with asthma had secondhand e-cig aerosol exposure, which was associated with an increased risk for having an asthma attack (7). Furthermore, emerging data from the vaping-related pulmonary illness cases in Illinois and Wisconsin indicate a higher-than-expected occurrence in asthmatics (1). At the University of North Carolina, we recently described two case reports of adolescent asthmatics e-cigarette users who presented with life-threatening status asthmaticus necessitating veno-venous extracorporeal membrane oxygenation (VV-ECMO) (8). The available data clearly show that vaping among adolescent asthmatics is common and that these users may present a uniquely susceptible population for adverse effects of vaping.

The Route of Exposure Matters:

No specific single additive or substance has been determined to be responsible for EVALI. However, multiple cases have involved user modification of e-liquids to include cannabinoids such as CBD and THC, and solvents such as medium chain triglycerides (MCTs) and vitamin E acetate (1). It remains unclear whether substances added by the user, substances added by manufacturers, or a combination of both are responsible for the current cases of lung injury. Most substances used in e-liquid formulations are recognized as food-safe; however, the vast

majority food-grade chemicals have not been tested for inhalation safety (2). Vapers may believe that all substances which are safe to eat are broadly safe regardless of how they are consumed. A common example of a food-safe flavoring agent with recognized inhalation toxicity is diacetyl. Inhalation of diacetyl (2,3-butanedione), a common flavoring agent used to provide a buttery or creamy flavor, caused acute onset bronchiolitis obliterans, an irreversible obstructive lung disease, in workers at a microwave popcorn production facility who were exposed to aerosolized flavoring agents (2). Exposures that are benign for the skin or gastrointestinal track may pose a serious threat to the lungs due to variability in epithelial defenses and the expression of detoxifying enzymes. For example, keratin provides the skin and underlying tissues with a physical barrier against dermal exposures, and the gastrointestinal tract and liver have robust expression of Phase I and Phase II drug metabolizing enzymes, such as cytochrome P450 oxidases, which catalyze the metabolic breakdown and detoxification process of xenobiotics. The lungs have evolved other effective defense mechanisms, including a protective airway surface liquid milieu, mucociliary clearance, epithelial tight junctions, and resident lymphocyte populations, to protect the body against common environmental toxicants. However, it is entirely unclear how well these defenses will withstand new and emerging insults, such as those produced when vaping. Paracelsus termed the guiding principle of Toxicology “The dose makes the poison”, but in the context of flavored e-cigarettes, this statement should be amended to include that “The route of exposure makes the poison”.

The Centers for Disease Control and Prevention (CDC) is continuing to collect data on potential components common to e-liquids used by patients with EVALI. The clinical manifestation of EVALI can include lipid pneumonia, characterized by lipid laden macrophages in the lung (1). Inhalation of lipid aerosols, such as through inadvertent aspiration of lipid substances, can cause lipid pneumonia. Vitamin E acetate, a lipid commonly added to facial moisturizers and skin creams, has been identified in some, but not all of the e-cigarette products associated with EVALI. Numerous vaping blogs describe the frequent use of Vitamin E acetate to dilute concentrated cannabinoids. Additionally, these substances have been used to adulterate bootleg THC cartridges to make them appear thicker and more similar to commercial THC cartridges. Vaping blogs and vape shops warn against adding lipids to any e-liquid as the aerosolization and inhalation of lipid aerosols will cause lipid pneumonia. However, the etiology of lipid pneumonia can also be endogenous. A recent study reports that lipid laden macrophages may be caused by disruption of the lung lipid homeostasis following chronic exposure to inhaled base e-liquid components (e.g. propylene glycol and glycerol) and not

exogenous lipid inhalation (9). Moreover, chemical reactions between e-liquid components can result in the formation of secondary acetals and possibly tertiary reaction products with completely unknown or enhanced toxicity (10). This further illustrates that, in the absence of regulations over the manufacture and distribution of vaping products, we simply do not know what chemicals e-liquid manufacturers are using or what the biological consequences of inhalation will be.

What now?

Based on data from the 2019 Youth Tobacco Survey, there are now 5 million teenagers (over 27%) who are using e-cigarettes. While this survey shows that cigarette smoking rates are down to 5.8%, the sharp increase in e-cigarette use among teenagers represents a new generation of potentially nicotine-addicted individuals. Given the newly appreciated harms associated with vaping, urgent action to minimize this use is essential. Education of adolescents and young adults about VAPI by clinicians is an important first step. Appropriate and effective regulatory actions by the FDA to reduce the availability and appeal of e-cigarettes to adolescents is also crucial. Specifically, regulations directed towards banning e-liquids with “kid-friendly” flavorings, images, and packaging should be prioritized. The increased risk to persons with asthma makes this an especially important issue for the allergy and immunology community. Public health policies have effectively reduced tobacco use among children. Similar action is urgently needed for e-cigarette use, particularly among teenagers and young adults with asthma.

1. Layden JE, Ghinai I, Pray I, Kimball A, Layer M, Tenforde M, et al. Pulmonary Illness Related to E-Cigarette Use in Illinois and Wisconsin - Preliminary Report. *N Engl J Med*. 2019. Epub 2019/09/07. doi: 10.1056/NEJMoa1911614. PubMed PMID: 31491072.
2. Clapp PW, Jaspers I. Electronic Cigarettes: Their Constituents and Potential Links to Asthma. *Curr Allergy Asthma Rep*. 2017;17(11):79. Epub 2017/10/07. doi: 10.1007/s11882-017-0747-5. PubMed PMID: 28983782; PMCID: PMC5995565.
3. Hajek P, Phillips-Waller A, Przulj D, Pesola F, Myers Smith K, Bisal N, et al. A Randomized Trial of E-Cigarettes versus Nicotine-Replacement Therapy. *N Engl J Med*. 2019;380(7):629-37. Epub 2019/01/31. doi: 10.1056/NEJMoa1808779. PubMed PMID: 30699054.
4. Dai H, Leventhal AM. Association of electronic cigarette vaping and subsequent smoking relapse among former smokers. *Drug and alcohol dependence*. 2019;199:10-7. Epub 2019/04/13. doi: 10.1016/j.drugalcdep.2019.01.043. PubMed PMID: 30978519; PMCID: PMC6743978.
5. Polosa R, Campagna D, Sands MF. Counseling patients with asthma and allergy about electronic cigarettes: an evidence-based approach. *Ann Allergy Asthma Immunol*.

- 2016;116(2):106-11. Epub 2015/11/03. doi: 10.1016/j.anai.2015.10.012. PubMed PMID: 26522253.
6. Schweitzer RJ, Wills TA, Tam E, Pagano I, Choi K. E-cigarette use and asthma in a multiethnic sample of adolescents. *Preventive medicine*. 2017;105:226-31. Epub 2017/10/02. doi: 10.1016/j.ypmed.2017.09.023. PubMed PMID: 28964850; PMCID: PMC5653431.
7. Bayly JE, Bernat D, Porter L, Choi K. Secondhand Exposure to Aerosols From Electronic Nicotine Delivery Systems and Asthma Exacerbations Among Youth With Asthma. *Chest*. 2019;155(1):88-93. Epub 2018/10/26. doi: 10.1016/j.chest.2018.10.005. PubMed PMID: 30359612.
8. Bradford LE, Rebuli ME, Ring BJ, Jaspers I, Clement KC, Loughlin CE. Danger in the vapor? ECMO for adolescents with status asthmaticus after vaping. *The Journal of asthma : official journal of the Association for the Care of Asthma*. 2019:1-5. Epub 2019/07/30. doi: 10.1080/02770903.2019.1643361. PubMed PMID: 31352844.
9. Madison MC, Landers CT, Gu BH, Chang CY, Tung HY, You R, et al. Electronic cigarettes disrupt lung lipid homeostasis and innate immunity independent of nicotine. *J Clin Invest*. 2019. Epub 2019/09/05. doi: 10.1172/jci128531. PubMed PMID: 31483291.
10. Erythropel HC, Jabba SV, DeWinter TM, Mendizabal M, Anastas PT, Jordt SE, et al. Formation of flavorant-propylene Glycol Adducts With Novel Toxicological Properties in Chemically Unstable E-Cigarette Liquids. *Nicotine & tobacco research : official journal of the Society for Research on Nicotine and Tobacco*. 2018. Epub 2018/10/20. doi: 10.1093/ntr/nty192. PubMed PMID: 30335174.

Figure legend:

Figure 1: The Route of Exposure Determines Toxicity. Components contained in e-cigarettes and vaping products, such as flavoring agents, are safe for ingestion but cause toxicity in the lung upon inhalation. Similarly, compounds, such as Vitamin E and coconut oil, which have been identified in many vaping products associated with EVALI, are safe for ingestions or absorption through the skin. However, thermal oxidation, occurring as part of the vaporization process, and changing their route of exposure to inhalation likely modifies their toxic potential.

The Route of Exposure Determines Toxicity

